

In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.
Further profit growth; Sales up 16%;
Profit before R&D up 19%;
Net profit (group share) up 12%;
Acceleration of R&D expenditure
The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.